Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.51 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8707010 | 0.99 | CYP2D6 (0.56) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8702938 | 0.85 | CYP2D6 (0.65) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL10336594 | 0.84 | NR2E1 (0.69) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8703202 | 0.84 | CYP2D6 (0.58) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL8703573 | 0.84 | CYP2D6 (0.64) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8702732 | 0.84 | CYP2D6 (0.64) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8709242 | 0.82 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8708818 | 0.82 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8703394 | 0.82 | CYP2D6 (0.57) | CYP2D6HTR2AABCB1ADRB2ADRB1 | |
| SCHEMBL8708750 | 0.82 | CYP2D6 (0.63) | CYP2D6HTR2AABCB1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |